Product
Patsnap Eureka
For R&D, Patsnap Eureka makes reading and utilizing patents & technical documents easy.
Patsnap Eureka AIR
Designed for self-driven R&D workflows. Generate viable solutions, solve complex R&D challenges, empower your innovation with AI.
Patsnap Eureka Materials
Designed for material experts only. Revolutionize your material R&D, from search, analyze, to developing new materials.
Feature
TechResearch
Generate reliable direction feasibility study reports for your R&D in just a few steps.
TechSeek
Discover and master advanced knowledge NOW. Basics, ideas, possibilities, all at once.
TechMind
As an expert in R&D Theories, TechMind can generates customized viable solutions instantly.
TechRisk
Analyze your overall solution with one click, know your potential R&D risks in advance.
TechMonitor
Get weekly tech updates, stay abreast of the latest tech innovations and key insights.
Patents
Literature
Hiro is an intelligent assistant for R&D personnel, combined with Patent DNA, to facilitate innovative research.
35 results about "Anti muscarinic" patented technology
Efficacy Topic
Property
Owner
Technical Advancement
Application Domain
Technology Topic
Technology Field Word
Patent Country/Region
Patent Type
Patent Status
Application Year
Inventor
Anti-Muscarinic Drugs May Reverse Peripheral Neuropathy. By blocking muscarinic receptors, some drugs already on the market could be used to prevent, or even reverse, the process of nerve degeneration common in axonopathic diseases, including diabetes.
Transdermally administered tolterodine as anti-muscarinic agent for the treatment of overactive bladder
InactiveUS6517864B1Achieve effectClinical efficacyOrganic active ingredientsAerosol deliveryMuscarinic antagonistMetabolite
Device for transdermal administration of tolterodine, optionally encompassing salts, prodrugs and metabolites thereof, optionally together with pharmaceutically acceptable carrier(s) to a human being or an animal in order to achieve an effect against overactive bladder. Use of a compound having an effect against overactive bladder comprising tolterodine, optionally encompassing salts, prodrugs and metabolites thereof, and optionally together with pharmaceutically acceptable carrier(s), for the manufacture of a composition to be administered transdermally for achieving an effect against overactive bladder. Method for achieving an effect against overactive bladder in a living body by transdermal administration of a compound comprising tolterodine, optionally encompassing salts, prodrugs and metabolites thereof, and optionally together with pharmaceutically acceptable carrier(s).
Owner:MCNEIL AB +1
Therapy for the treatment of disease
ActiveUS20070053995A1Relieve constipationBiocideNervous disorderAnticholinergic agentsCompound (substance)
Disclosed herein are pharmaceutical compositions comprising various combinations of an antimuscarinic or an anticholinergic agent, a compound that causes stimulation of salivary glands, and a compound that relieves constipation. Also disclosed are methods of treating a patient suffering from overactive bladder comprising administering to the patient the above pharmaceutical composition.
Owner:THERAVIDA INC
Methods for treating pain using smooth muscle modulators and a2 subunit calcium channel modulators
InactiveUS20060264509A1Limited efficacyReduce patient complianceBiocideOrganic active ingredientsGabapentinAdrenergic receptor agonists
A method is provided for using α2δ subunit calcium channel modulators or other compounds that interact with the α2δ calcium channel subunit in combination with one or more compounds with smooth muscle modulatory effects to treat pain. According to the present invention, α2δ subunit calcium channel modulators include GABA analogs (e.g., gabapentin and pregabalin), fused bicyclic or tricyclic amino acid analogs of gabapentin, and amino acid compounds. Compounds with smooth muscle modulatory effects include antimuscarinics, β3 adrenergic agonists, spasmolytics, neurokinin receptor antagonists, bradykinin receptor antagonists, and nitric oxide donors.
Owner:DYNOGEN PHARM INC
Methods for treating urinary incontinence and other disorders using trospium
InactiveUS6974820B2Potent activityAvoiding concomitant liabilityBiocideAnimal repellantsDiseaseSide effect
Owner:BRIDGE PHARMA INC
Transdermally administered tolterodine as anti-muscarinic agent for the treatment of overactive bladder
InactiveUS20030124179A1Clinical efficacyReduce riskBiocideOrganic active ingredientsMuscarinic antagonistNasal cavity
The present invention is drawn to set of formulations of at least one compound selected from tolterodine, salts thereof, prodrugs thereof and / or metabolites thereof, wherein in the set of formulations contains at least one device for transdermal administration and at least one formulation for oral, sublingual, buccal, nasal, pulmonary, rectal and / or other transmucosal administration, in order to achieve an effect against overactive bladder and / or symptoms associated with this condition. The present invention is further drawn to methods of treating an overactive bladder with the formulations.
Owner:MCNEIL AB
Methods for treating lower urinary tract disorders using alpha2delta subunit calcium channel modulators with smooth muscle modulators
Owner:EDUSA PHARMA
Therapy for the treatment of disease
Disclosed herein are pharmaceutical compositions comprising various combinations of an antimuscarinic or an anticholinergic agent, a compound that causes stimulation of salivary glands, and a compound that relieves constipation. Also disclosed are methods of treating a patient suffering from overactive bladder comprising administering to the patient the above pharmaceutical composition.
Owner:THERAVIDA INC
Compositions comprising an antimuscarinic and a long-acting beta-agonist
InactiveUS20090181935A1Substantial therapeutic benefitQuick effectBiocideAnimal repellantsDermatologyAirways disease
Compositions which comprise a combination of a salt of 3-[[[(3-fluorophenyl)[(3,4,5-trifluoro phenyl)methyl]amino]carbonyl]oxy]-1-[2-oxo-2-(2-thienyl)ethyl]-1-azoniabicyclo [2.2.2]octane, and a long-acting phenylalkylamino beta2-agonist are effective for the prevention and treatment of inflammatory or obstructive airways diseases.
Owner:CHIESI FARM SPA
Methods for treating urinary incontinence and other disorders using trospium
InactiveUS20050043342A1Potent activityAvoiding concomitant liabilityBiocideAnimal repellantsDiseaseSide effect
Methods are disclosed using Trospium Chloride, an antimuscarinic smooth muscle relaxant, for the treatment of urinary incontinence, and other disorders, while avoiding the concomitant liability of adverse side effects associated with other antimuscarinic drugs.
Owner:BRIDGE PHARMA INC
Methods for decreasing detrusor muscle overactivity
InactiveUS20050239890A1Limited efficacyReduce patient complianceBiocideOrganic active ingredientsDiseaseGabapentin
A method is provided for using α2δ subunit calcium channel modulators or other compounds that interact with the α2δ calcium channel subunit in combination with one or more compounds with smooth muscle modulatory effects to treat and / or alleviate the symptoms associated with painful and non-painful lower urinary tract disorders in normal and spinal cord injured patients. According to the present invention, α2δ subunit calcium channel modulators include GABA analogs, e.g., gabapentin and pregabalin, fused bicyclic or tricyclic amino acid analogs of gabapentin, and amino acid compounds. Compounds with smooth muscle modulatory effects include antimuscarinics, β3 adrenergic agonists, spasmolytics, neurokinin receptor antagonists, bradykinin receptor antagonists, and nitric oxide donors.
Owner:DYNOGEN PHARM INC
Methods for treating smooth muscle contractions using trospium
InactiveUS20060293356A1Potent activitySafely be used as treatmentBiocideMuscular disorderDiseaseSide effect
Methods are disclosed using trospium, an antimuscarinic smooth muscle relaxant, for the treatment of smooth muscle disorders, while avoiding the concomitant liability of adverse side effects associated with conventional antimuscarinic treatment.
Owner:BRIDGE PHARMA INC
Methods for treating lower urinary tract disorders using alpha2delta subunit calcium channel modulators with smooth muscle modulators
InactiveUS20060247311A1Need lessLimited efficacyBiocidePeptide/protein ingredientsDiseaseGabapentinoid
A method is provided for using α2δ subunit calcium channel modulators or other compounds that interact with the α2δ calcium channel subunit in combination with one or more compounds with smooth muscle modulatory effects to treat and / or alleviate the symptoms associated with painful and non-painful lower urinary tract disorders in normal and spinal cord injured patients. According to the present invention, α2δ subunit calcium channel modulators include GABA analogs (e.g. gabapentin and pregabalin), fused bicyclic or tricyclic amino acid analogs of gabapentin, and amino acid compounds. Compounds with smooth muscle modulatory effects include antimuscarinics, β3 adrenergic agonists, spasmolytics, neurokinin receptor antagonists, bradykinin receptor antagonists, and nitric oxide donors.
Owner:DYNOGEN PHARM INC
Novel methods
The invention provides methods of inhalation treatment of a respiratory disease or condition in a patient in need to such treatment without producing in said patient systemic antimuscarinic effects, comprising administering to said patient an effective amount of aclidinium.
Owner:ALMIRALL
Methods and compositions for treatment of nicotine dependence and dementias
InactiveUS20050277626A1Easy to useIncrease heightBiocideNervous disorderTricyclic antidepressantTricyclic anti-depressants
In accordance with the present invention, it has been unexpectedly found that the administration of an acetylcholinesterase inhibitor in combination with a tricyclic antidepressant having anti-muscarinic properties provides a highly effective and well tolerated treatment for nicotine dependence and dementias, such as Alzheimer's disease (AD). In one aspect, it is effective in the treatment of nicotine dependence, as well as in the treatment and mitigation of nicotine withdrawal symptoms and in the effectuation of smoking cessation. In another aspect, it is effect in the treatment and mitigation of dementias such as Alzheimer's disease.
Owner:NEUROCURE
Combined Use of an Alpha-Adrenergic Receptor Antagonist and an Anti-Muscarinic Agent
The combined use of (R)-5-(2-{[2-(2-ethoxyphenoxy)ethyl]amino}propyl)-2-methoxybenzene-1-sulfonamide (tamsulosin), or its pharmaceutically acceptable salt, and (1S)-1-phenyl-1,2,3,4-tetrahydroisoquinoline-2-carboxylic acid (3R)-quinuclidin-3-yl ester (solifenacin), or its pharmaceutically acceptable salt, for the preparation Of a medicament for the improvement of lower urinary tract symptoms associated with benign prostatic hyperplasia (LUTS / BPH) with a substantial storage component is provided.
Owner:ASTELLAS IRELAND
Methods for relaxation of smooth muscle contractions using Trospium
InactiveUS20070004766A1Improve usabilityImproved profileBiocideAnimal repellantsSide effectAntimuscarinic drug
Methods are disclosed using Trospium Chloride, an antimuscarinic smooth muscle relaxant, for the treatment of urinary incontnence, while avoiding the concomitant liability of adverse side effect associated with other antimuscarinic drugs.
Owner:BRIDGE PHARMA INC
Methods for treating functional bowel disorders using alpha2 subunit calcium channel modulators with smooth muscle modulators
InactiveUS20060276542A1Limited efficacyReduce patient complianceBiocidePeptide/protein ingredientsGabapentinoidAdrenergic receptor agonists
A method is provided for using α2δ subunit calcium channel modulators or other compounds that interact with the α2δ calcium channel subunit in combination with one or, more compounds with smooth muscle modulatory effects to treat functional bowel disorders in patients in need of treatment. According to the present invention, α2δ subunit calcium channel modulators include GABA analogs including gabapentin and pregabalin, fused bicyclic or tricyclic amino acid analogs of gabapentin, and amino acid compounds. Compounds with smooth muscle modulatory effects include antimuscarinics, β3 adrenergic agonists, spasmolytics, neurokinin receptor antagonists, bradykinin receptor antagonists, and nitric oxide donors.
Owner:DYNOGEN PHARM INC
Methods for treating urinary incontinence in patients suffering from memory disorders
InactiveUS7390816B2Potent activitySafely be used as treatmentBiocideMuscular disorderDiseaseSide effect
Methods are disclosed using trospium, an antimuscarinic smooth muscle relaxant, for the treatment of smooth muscle disorders, while avoiding the concomitant liability of adverse side effects associated with conventional antimuscarinic treatment.
Owner:BRIDGE PHARMA INC
Pharmaceutical composition containing alpha-adrenergic receptor antagonist and an Anti-muscarinic agent and method of improving lower urinary tract symptoms associated with prostatic hypertrophy
InactiveUS20100331361A1Symptoms improvedSafe and effectiveBiocideUrinary disorderEccentric hypertrophyAdrenergic antagonist
A pharmaceutical composition including active ingredients of (R)-5-(2-{[2-(2-ethoxyphenoxy)ethyl]amino}propyl-2-methoxybenzene-1-sulfonamide and (1S)-1-phenyl-1,2,3,4-tetrahydroisoquinoline-2-carboxylic acid (3R)-quinuclidin-3-yl ester, or their pharmaceutically acceptable salts, provides improvement of lower urinary tract symptoms associated with prostatic hypertrophy. The active ingredients may be administered either simultaneously or at a time interval. The pharmaceutical composition also provides significant improvement of lower urinary tract symptoms associated with benign prostatic hyperplasia having a substantial storage component.
Owner:ASTELLAS PHARMA INC +1
Treatment of cancer with Anti-muscarinic receptor agents
InactiveUS20090010923A1Reduce the possibilityReduce muscarinic receptor-mediated transactivationCompounds screening/testingOrganic active ingredientsCancer researchTransactivation
The present invention relates to methods of treating proliferative disorders of colon cells. The methods comprise administering to the cells an effective amount of at least one agent to reduce M3 muscarinic receptor-mediated transactivation of at least one epidermal growth factor receptor.
Owner:THE GOVERNMENT OF THE UNITED STATES OF AMERICA AS REPRESENTED BY THE DEPT OF VETERANS AFFAIRS
Combination therapy using a beta 3 adrenergic receptor agonist and an antimuscarinic agent
Described herein is an improved method of treating overactive bladder, wherein the method comprises administering to a patient in need thereof a beta 3 adrenergic receptor agonist, an antimuscarinic agent, and an optional selective M2 antagonist. Such combination therapy provides improved efficacy and / or reduced side effects.
Owner:SCHERING AG
Combination of alpha-2 receptor agonist (clonidin) and an anti-muscarinic agent (oxybutynin) for the treatment of sialorrhoea
InactiveCN101400347AReduce trafficNo side effectsOrganic active ingredientsDrug compositionsOxybutyninMuscarinic antagonist
An alpha2 adrenoreceptor agonist eg. clonidine, brimonidine, monoxidine, lofexidine is useful for the treatment of siaiorrhoea, administered by the paraungual, sublingual or buccal route. The patient to be treated is also given an anti-muscarinic agent eg. oxybutynin, glycopyrrolate, ipratropium.
Owner:东方药业(萨摩亚)有限公司
Liquid propellant-free formulation comprising an antimuscarinic drug
Liquid, propellant-free pharmaceutical formulation for administration by nebulization which comprising an antimuscarinic drug as active ingredient are useful for the prevention and / or treatment of a wide range of conditions including respiratory disorders.
Owner:CHIESI FARM SPA
Combination of alpha-2 receptor agonist (clonidin) and Anti-muscarinic agent (oxybutynin) for the treatment of sialorrhoea
ActiveUS20090221659A1Good effectEliminate side effectsOrganic active ingredientsBiocideOxybutyninGlycopyrrolate
An alpha2 adrenoreceptor agonist eg. clonidine, brimonidine, monoxidine, lofexidine is useful for the treatment of siaiorrhoea, administered by the paraungual, sublingual or buccal route. The patient to be treated is also given an anti-muscarinic agent eg. oxybutynin, glycopyrrolate, ipratropium.
Owner:ORIENT PHARMA SAMOA
Composition, formulations & kit for treatment of respiratory and lung disease with dehydroepiandrosterone(s) steroid & an Anti-muscarinic agent(s)
A pharmaceutical or veterinary composition comprises a non-corticosteroids, and / or salts thereof, and an anti-muscarinic (anti-cholinergic) agent, and / or pharmaceutically or veterinarily acceptable salts thereof. The composition is provided in various formulations and in the form of a kit. The products of this patent are useful in the prophylaxis and treatment of various respiratory, lung and malignant diseases.
Owner:EPIGENESIS PHARMA LLC
Method for Alleviating Symptoms of Urinary Incontinence
A method for alleviating urinary incontinence, by administering to a subject, including, but not limited to, climacteric women, a therapeutically effective amount of an anticholinergic agent. The anticholinergic agent may be an anti-muscarinic agent, and preferably, the anti-muscarinic agent may be homatropine, including its methylbromide salt.
Owner:EATON SCI SYST
Combination of alpha-2 receptor agonist (clonidin) and Anti-muscarinic agent (oxybutynin) for the treatment of sialorrhoea
ActiveUS20120316213A1Good effectEliminate side effectsBiocideOrganic active ingredientsOxybutyninGlycopyrrolate
An alpha2 adrenoreceptor agonist eg. clonidine, brimonidine, monoxidine, lofexidine is useful for the treatment of siaiorrhoea, administered by the paraungual, sublingual or buccal route. The patient to be treated is also given an anti-muscarinic agent eg. oxybutynin, glycopyrrolate, ipratropium.
Owner:ORIENT PHARMA SAMOA
Quaternary antimuscarinic compounds for the treatment of bladder diseases
The present invention relates to a method for treating bladder disease, including urinary incontinence, which involves intravesical administration of quaternary antimuscarinic compounds having longer duration of effect and fewer side effects than standard treatments.
Owner:UNIVERSITY OF ROCHESTER
2-(2,2-diarylvinyl)-quaternary ammonium salt type cyclic amine derivative and preparation method thereof
PendingCN110981787ANovel structureHas anticholinergic activityNervous disorderOrganic chemistryAntagonismOrtho position
The invention provides a quaternary ammonium salt type 2-(2,2-diarylvinyl)cyclic amine derivative and a preparation method thereof, wherein the aryl substituent of the quaternary ammonium salt type 2-(2,2-diarylvinyl)cyclic amine derivative has hydroxyl or a hydroxyl derivative group at the ortho-positions of vinyl. The biological activity test results show that the compound has good muscarinic receptor antagonism activity, and can be used as an active pharmaceutical ingredient in treatment of diseases related to muscarinic receptor antagonism.
Owner:TAIZHOU GUOKEHUAWU BIOMEDICAL TECH CO LTD
Combination of an antiallergic agent with muscarinic antagonist and/or dopaminergic agonist for use in preventing/stopping of axial myopia in human
One of the major issues against the use of muscarinic antagonists or dopamine agonist eyedrops for the controlling of eye growth and prevention of myopia is the unacceptable rate of iatrogenic conjunctivitis or dermatitis. This invention relates to the association of those active principles with an antiallergic component. In alternative the ophthalmic use of a molecule that simultaneously has an antimuscarinic and / or dopaminergic action along with an antihistaminic function.
Owner:DAMBROSIO ENZO MARIA
Who we serve
- R&D Engineer
- R&D Manager
- IP Professional
Why Patsnap Eureka
- Industry Leading Data Capabilities
- Powerful AI technology
- Patent DNA Extraction
Social media
Patsnap Eureka Blog
Learn More Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic, Popular Technical Reports.
© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap|About US| Contact US: help@patsnap.com